View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 7, 2022

Cue Health unveils plans to develop Omicron-Genotyping Covid-19 Test

The Omicron-specific test will be designed to detect the latest variant in nasal samples.

Cue Health has announced plans to develop an Omicron-Genotyping Covid-19 test in partnership with the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The company stated that the test will complement its existing molecular Covid-19 test, which has the capability to identify all known variants of the disease, including the Omicron variant.

The new test will be used in professional point-of-care settings to specifically detect the Omicron variant in nasal samples.

It will be designed to be compatible with the Cue Health Mobile Application and Cue Health Monitoring System.

The new Covid-19 test will provide the latest health information to clinicians and researchers in order to support informed treatment as well as real-time containment decisions.

Cue Health plans to utilise the additional funding obtained from BARDA to speed up the test’s development, validation and regulatory authorisation process.

Cue Health co-founder and CEO Ayub Khattak said: “An Omicron-specific test will assist clinicians in providing patients better treatment options and containment strategies at the time of a positive diagnosis.

“We are proud to partner with BARDA to develop this new test, which will help eliminate guesswork, provide more choices for patients and strengthen public health outcomes for communities.”

Since 2018, the company has been working with BARDA, receiving $30m in base funding.

BARDA awarded $13m to Cue Health in March 2020 to fast-track the development, validation and Food and Drug Administration (FDA) clearance of a molecular diagnostic test.

Last month, Cue Health received authorisation from the Health Sciences Authority (HSA) in Singapore for its molecular Covid-19 test for self-testing.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network